Compare Biogen Inc (BIIB) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Transocean Ltd — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Transocean Ltd trades at $5.8 (market cap $6.49B). The key difference: Biogen Inc is far larger — about 4.6× Transocean Ltd's market cap, and Biogen Inc is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| BIIB | RIG | |
|---|---|---|
Market Cap | $30.13B | $6.49B |
Sector | Health | Technology |
52-Week High | $216.63 | $7.58 |
52-Week Low | $128.93 | $2.80 |
Enterprise Value | $37.20B | $11.10B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
